Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan to initiate Part 2 of its Phase…
All articles by Salong Debbarma
Salong Debbarma
-
-
Dignify Therapeutics secures FDA clearance for Phase I DTI-117 trial
Dignify Therapeutics has secured investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to advance DTI-117…
-
FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib
Enliven Therapeutics has reached an agreement with the US Food and Drug Administration (FDA) regarding the final protocol for the…
-
Viking Therapeutics begins study of oral VK2735 for obesity
Viking Therapeutics has commenced the second part of a clinical trial evaluating oral maintenance dosing schedules of its dual glucagon-like…
-
AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
AbbVie and Genmab have reported positive topline data from the Phase III EPCORE DLBCL-2 trial of epcoritamab combined with standard…
-
First patient dosed in Vial’s Phase Ib trial of IL-13 x TSLP antibody
Clinical-stage biotechnology company Vial has dosed the first patient in its Phase Ib clinical study evaluating interleukin-13 × thymic stromal…
-
Surrozen secures FDA clearance for SZN-8141 clinical trial
The US Food and Drug Administration (FDA) has cleared Surrozen’s investigational new drug (IND) application for SZN-8141 to begin clinical…
-
Genmab reports Phase I/II data for Rina-S in ovarian cancer
Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients…
-
R1 Therapeutics secures $80.5m to fund Phase IIb AP306 study
US-based R1 Therapeutics has expanded its Series A financing to $80.5m to advance its lead asset, AP306, in a Phase…
-
MSD’s Phase IIb study of tulisokibart achieves primary endpoint
Merck & Co (MSD) has reported that the Phase IIb MK-7240-012 study of its investigational humanised monoclonal antibody, tulisokibart, achieved…